A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
Clinical trial NCT05773092 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05773092
- Sponsor
- National Cancer Centre, Singapore
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-01
- Primary completion
- 2025-10-24
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.